Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York City, NY, shares the results of a study evaluating the impact of lenalidomide on second primary malignancies (SPM) development when used at induction and maintenance therapy for patients with multiple myeloma. Overall, the data demonstrated that there was very little risk of SPM development with lenalidomide, with only a few incidences of skin cancer recorded. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть